Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Revolution Medicines Inc - Ordinary Shares | Sugemalimab - (GEMSTONE-201) | T-cell lymphoma / Stage IV non-small cell lung cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Revolution Medicines Inc - Ordinary Shares | RMC-4630-03 and Sotorasib (AMG 510) | Lung cancer | Phase 2 | Looking for Funding | RMC-4630-03: Oral Sotorasib AMG 510: Oral | Oncology |
| Rezolute Inc. | Ersodetug (RZ358) - (upLIFT) | Hypoglycemia caused by tumor HI | Phase 3 | Ongoing | Intravenous | Endocrinology |
| Rezolute Inc. | RZ358 | Hypoglycemia in patients with tumor hyperinsulinism (HI) | Phase 3 | IND Clearance | Intravenous | Endocrinology |
| Rezolute Inc. | RZ358 - (sunRIZE) | Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia | Phase 2b | Data Released | Intravenous | Endocrinology |
| Rezolute Inc. | RZ402 | Diabetic macular edema (DME) | Phase 2 | Data Released | Oral | Opthalmic |
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (TRANSCEND) | Hypothalamic obesity | PDUFA priority review | Ongoing | Subcutaneous | Endocrinology |
| Rhythm Pharmaceuticals Inc. | Setmelanotide - (EMANATE) | Heterozygous POMC/PCSK1 obesity; heterozygous LEPR obesity; variants of SH2B1 genes; PCSK1 N221D deletions | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
